Process for Effecting the Relaxation of Muscles of a Human by Means of Fragrance
Described is a process for effecting the relaxation of a tensive back, shoulder or neck muscle of a human mammal for a substantial period of time. The process of our invention consists essentially of the step of continuously or periodically administering to said human mammal through inhalation over a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing period of time, a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing quantity and concentration of one or more fragrance compositions having an aroma profile including one or more of a rose, floral, musky, ambery, sweet and/or powdery aroma notes.
1 . A process for effecting the relaxation to the back, shoulder or neck muscle of a human mammal for a substantial period of time consisting essentially of the step of continuously or periodically administering to said human mammal through inhalation a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing period of time a stress reactivity-reducing, tensive back, stress reactivity-reducing shoulder or stress reactivity-reducing neck muscle-relaxing quantity and concentration of one or more fragrance compositions of matter wherein the fragrance composition administered comprises hexahydro-4,6,6,7,8,8-hexamethylcyclopenta-γ-2-benzopyran, trans methyl dihydrojasmonate, 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-acetonaphthone, p-t-butyl-α-methyldihydrocinnamic aldehyde, β-phenylethyl alcohol, ethylene brassylate, bergamot oil, ethyl linalool, 2-methyl-3-(p-methoxyphenyl) propanal, and linalyl acetate.
2 . A process for effecting the relaxation to the back, shoulder or neck muscle of a human mammal for a substantial period of time consisting essentially of the step of continuously or periodically administering to said human mammal through inhalation a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing period of time a stress reactivity-reducing, tensive back, stress reactivity-reducing shoulder or stress reactivity-reducing neck muscle-relaxing quantity and concentration of one or more fragrance compositions of matter wherein the fragrance composition administered comprises methyl dihydrojasmonate, 4-(4-hydroxy-4-methylpentyl)-3-cyclohexene-1-carboxaldehyde, heliotropine, vanillin, ethyl vanillin, coumarin, bergamot oil, β-phenylethylalcohol, and linalool.
3 . The process of claim 1 which is a process for effecting the relaxation to the back, shoulder or neck muscle of a human mammal having a weight, of from about 50 pounds up to about 300 pounds, each of which back, shoulder or neck muscle has an initial magnitude of tension as measured by the Stroop task period muscle activity, in the range of from about 0.5 microvolts up to about 10.0 microvolts, for a period of time, in the range of from about 1 minute up to about 24 hours, consisting essentially of the step of continuously or periodically administering to said human mammal through inhalation over a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing period of time, in the range of from about 1 minute up to about 24 hours, a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing (i) quantity, in the range of from about 6 nanograms up to about 500 micrograms, (ii) concentration, C of from about 1 nanogram per liter up to about 125 micrograms per liter, and (iii) inhalation rate, of from about 1 microgram/hour up to about 45 milligrams/hour, of fragrance compositions comprising hexahydro-4,6,6,7,8,8-hexamethylcyclopenta-γ-2-benzopyran, trans methyl dihydrojasmonate, 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-acetonaphthone, p-t-butyl-α-methyldihydrocinnamic aldehyde, β-phenylethyl alcohol, ethylene brassylate, bergamot oil, ethyl linalool, 2-methyl-3-(p-methoxyphenyl) propanal, and linalyl acetate, and the resulting magnitude of back muscle tension, is in the range of from about 0.4 microvolts up to about 3.3 microvolts and wherein the initial muscle tension is greater than at least about 1.05 times the final magnitude of tension.
4 . The process of claim 2 which is a process for effecting the relaxation to the back, shoulder or neck muscle of a human mammal having a weight, of from about 50 pounds up to about 300 pounds, each of which back, shoulder or neck muscle has an initial magnitude of tension as measured by the Stroop task period muscle activity, in the range of from about 0.5 microvolts up to about 10.0 microvolts, for a period of time, in the range of from about 1 minute up to about 24 hours, consisting essentially of the step of continuously or periodically administering to said human mammal through inhalation over a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing period of time, in the range of from about 1 minute up to about 24 hours, a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing (i) quantity, in the range of from about 6 nanograms up to about 500 micrograms, (ii) concentration, C of from about 1 nanogram per liter up to about 125 micrograms per liter, and (iii) inhalation rate, of from about 1 microgram/hour up to about 45 milligrams/hour, of fragrance compositions comprising methyl dihydrojasmonate, 4-(4-hydroxy-4-methylpentyl)-3-cyclohexene-1-carboxaldehyde, heliotropine, vanillin, ethyl vanillin, coumarin, bergamot oil, β-phenylethylalcohol, and linalool, and the resulting magnitude of back muscle tension, is in the range of from about 0.4 microvolts up to about 3.3 microvolts and wherein the initial muscle tension is greater than at least about 1.05 times the final magnitude of tension.
5 . The process of claim 1 wherein the back, shoulder or neck muscle relaxed is the top layer Trapezius muscle.
6 . The process of claim 2 wherein the back, shoulder or neck muscle relaxed is the top layer Trapezius muscle.
7 . The process of claim 3 wherein initial magnitude of tension is greater than at least about 1.10 times the final magnitude of tension.
8 . The process of claim 4 wherein initial magnitude of tension is greater than at least about 1.10 times the final magnitude of tension.
9 . The process of claim 3 wherein the initial magnitude of tension is greater than at least about 1.25 times the final magnitude of tension.
10 . The process of claim 4 wherein the initial magnitude of tension is greater than at least about 1.25 times the final magnitude of tension.